OBJECTIVES:
This study attempts to investigate the impact of national mass screening program on health service utilizations and medical expenses. METHODS: Main data is consisted of the subjects (12,449,964) eligible for 2002 screening program provided by the National Health Insurance who were born in even year. To analyze the effect of screening in the case of hypertension, we excluded people who had any medical records of hypertension before 2002. After sorting and random sampling 5%(564,443), we extracted the subjects' medical payments for hypertension complications in 2007. The independent variable of interest is whether screened or not, and the dependent variables are the incidence and costs of hypertension complications. We compared the results obtained using instrumental variable methods with those from conventional logistic and linear regression models. RESULTS: Conventional logistic and multiple regression models suggest that the possibility of utilizing medical services is significantly higher in no-screen group and the average medical cost of hypertension complications reduced by 5% in screen group at 10% significant level. However, the results estimated using instrumental variable methods show different results. The screen group has significantly lower possibility to use medical service (pϽ0.05), but the lower average costs in screen group is not significant any more.
CONCLUSIONS:
The different results demonstrate that conventional regression approaches may have limitations in making causal inference using non-experimental data. This study shows that whether one gets medical screen or not affects the possibility of hypertension complications occurring, however it doesn't significantly relate to average costs. 
PCV141 CURRENT MANAGEMENT PATHWAY OF PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN GREECE. RESULTS FROM APTORII STUDY

OBJECTIVES:
To describe current management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) over 12 months in Greece. METHODS: Prospective observational study in ACS patients undergoing PCI from September 2008 -April 2009, capturing current practices over 12 months. RESULTS: Twenty-two sites enrolled 558 eligible patients: 351 patients had unstable angina or non-ST elevation myocardial infarction (UA/NSTEMI) and 207 STelevation myocardial infarction (STEMI). Median age was 64 years (IQR 55-73) (UA/ NSTEMI) and 56 years (IQR 49-66) (STEMI). Almost all patients (96.4%) received stents: 19% BMS only, 77.5% DES only and 3.5% both. 79% UA/NSTEMI and 86% STEMI patients were admitted to hospital within 1 day from start of ACS symptoms, while 78% UA/NSTEMI and 89% STEMI patients received the first antiplatelet loading dose (LD) in 1 day. Time from start of ACS symptoms to PCI was Յ3 days in 76% UA/NSTEMI and Յ1 day in 67% STEMI patients. Follow-up data were available for 540 (96.8%) patients. Percentage of patients on antiplatelets and other medications at hospital discharge and 12 months were as follows: aspirin 98%, 97%; clopidogrel 99%, 96%; statins 81%, 79%; beta-blockers 73%, 72%; calcium blockers 11%, 11%; angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors 64%, 62%; proton pump inhibitors 39%, 35%. A formal diet program was followed by 7% patients and a formal exercise program by 6% through the 1st year of follow up. CONCLUSIONS: In ACS patients treated with PCI in Greece, dual antiplatelet treatment is maintained in a very high percentage through one year post procedure, and DES use is also high. 
PCV142 A REVIEW OF THE PRIMARY CARE PRESCRIBING OF DABIGATRAN ETEXILATE AND RIVAROXABAN IN IRELAND
OBJECTIVES:
The objective was to analyse prescribing patterns of DBG and RIV on the GMS scheme in Ireland in 2010. METHODS: A retrospective analysis of the GMS prescribing database was performed. Analysis was performed using SAS (v9.1, SAS Institute Inc. Cary, US). RESULTS: 1098 patients had received DBG. Of these, 37.34% received it for longer than the maximum licensed duration of 35 days. Indeed, 15.94% received it for longer than 3 months and 7.56% for longer than 6 months. 1948 patients had received RIV. Of these, 25.77% had received it for longer than the maximum licensed duration of 35 days. Indeed, 2.1% had received it for longer than 3 months and 0.36% for longer than 6 months. CONCLUSIONS: This indicates that DBG and RIV may have been prescribed for unlicensed indications (for which positive reimbursement decisions have not yet been issued). Such indications include stroke prevention in AF and VTE treatment. There are efficacy, safety and budget impact concerns surrounding unlicensed prescribing. Also, should their licenses be extended in the future, prescribing for such indications may increase regardless of reimbursement decisions. There exists a need to introduce a policy in which drugs are only reimbursed for those indications which have received positive reimbursement decisions. 
PCV143 IMPLEMENTATION OF EVIDENCE-BASED NATIONAL GUIDANCE ON VENOUS THROMBO-EMBOLISM PROPHYLAXIS FOR HOSPITAL INPATIENTS IN ENGLAND
OBJECTIVES:
In 2007 the National Institute for Health and Clinical Excellence (NICE) published national guidance for VTE prevention. Hospitals have been expected to implement these preventive measures, beginning with systematic procedures for risk assessment of inpatients. We measured the compliance with NICE guidance in two hospitals in the South West of England two years after the publication of national guidance. METHODS: Systematic comparison of the implementation of national guidance on VTE prevention across two clinical specialities (general medicine, orthopaedics) in two hospitals in 2009, using 200 randomly selected longitudinal case studies, complemented by a qualitative study into their origins, development and practical responses to national guidance. Based on the criteria outlined in the NICE guidance we constructed a compliance score (minimum 0, maximum 5). RESULTS: We found a mixed picture of compliance with national VTE prevention guidance. Across both hospitals 90% of orthopaedic patients and 70% of general medical patients received VTE prophylaxis. In contrast, the prescribed risk assessment was not systematically carried out or documented: only 68% of orthopaedic and 35% of medical patients were formally risk-assessed. Hospital A achieved a compliance score of 1.28 (SD 0.76) in medicine and of 1.78 (SD 0.93) in orthopaedics. Hospital B achieved a score of 0.88 (SD 0.87) in medicine and of 1.69 (SD 0.59) in orthopaedics. CONCLUSIONS: Despite clear national guidance for VTE prevention, hospitals seem slow to implement, document or comply with the recommendation of individual risk assessment to guide the need for prophylaxis. As shown by the high levels of VTE prophylaxis administration in both hospitals and the qualitative interviews with senior clinicians, this is partially attributable to the fact that hospitals had strong internal guidance before the issue of national guidance. The added value of documenting individual VTE risk assessment is doubtful and limited compliance with national guidance is therefore not surprising. [APT] ) to prevent stroke in atrial fibrillation (AF) patients in relation to stroke risk. Given the limitations of vitamin K antagonists [e.g., warfarin], OAC is often underused, and less effective APT is prescribed instead or patients remain untreated. The objectives were: 1) To determine the type of antithrombotic therapy used by AF patients as stratified by stroke risk (using CHADS2 scores) in developed countries. 2) To assess quality of treatment with OAC by time in therapeutic range (TTR) of international normalized ratios (INR). METHODS: Studies were identified by literature review that reported 1) AF patients and treatment level categorized by CHADS2 score and 2) TTR for AF patients. RESULTS: In line with guidelines for AF treatment, as CHADS2 scores increased (i.e., higher risk for stroke), the percentage of patients receiving OACϮAPT increased and of patients receiving APT alone, or no treatment, decreased. A large number of moderate to high risk patients (based on CHADS2 scores), however, were still treated with AP alone (means: 25.6 -37.6%; range 0 -100%) or were untreated (means: 4.4 -10.6%; range:0.0 -26.3%). Thus, up to 48% were treated inappropriately. The reported proportion of treated patients with poor INR control ranged from 30-92% and varied according to TTR benchmark (Ͻ50% to Ͻ75% TTR). CONCLUSIONS: A large proportion of AF patients at moderate to high risk for stroke are suboptimally treated. Among those who do receive OAC treatment, many are poorly controlled and therefore receive little benefit. Using the CHA2DS2-VASc score, a more recent risk assessment tool, would result in even higher numbers of patients who are treated suboptimally. To prevent avoidable strokes among AF patients, there is a need for safe and effective treatments that require less complicated management (INR monitoring), therefore likely promoting higher compliance and persistence.
PCV144 STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION: INAPPROPRIATE ANTICOAGULATION AND POOR INR CONTROL
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